0R1B.L
Biogen Inc [0R1B.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0R1B.L Stock Summary
Top 10 Correlated ETFs
0R1B.L
Top 10 Correlated Stocks
0R1B.L
In the News
0R1B.L Financial details
Company Rating
Strong Buy
Market Cap
29.2B
Income
1.16B
Revenue
9.42B
Book val./share
102.14
Cash/share
7.25
Dividend
-
Dividend %
-
Employees
7.4K
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
25.34
Forward P/E
11.24
PEG
-4.11
P/S
3.71
P/B
2.56
P/C
27.32
P/FCF
34.92
Quick Ratio
0.9
Current Ratio
1.68
Debt / Equity
0.47
LT Debt / Equity
0.46
-
-
EPS (TTM)
8.03
EPS next Y
17.62
EPS next Q
-
EPS this Y
-61.75%
EPS next Y
119.44%
EPS next 5Y
201.78%
EPS last 5Y
-23.92%
Revenue last 5Y
-5.83%
Revenue Q/Q
-5.57%
EPS Q/Q
-465.96%
-
-
-
-
SMA20
-8.47%
SMA50
-17.84%
SMA100
-11.12%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
10%
ROC
0.09%
Gross Margin
64%
Oper. Margin
21%
Profit Margin
15%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
199.16-204.9332
52W High
-2.91%
52W Low
-0.47%
RSI
29.31
Rel Volume
-
Avg Volume
-
Volume
1.7K
Perf Week
-5.02%
Perf Month
-9.87%
Perf Quarter
-22.82%
Perf Half Y
-25.2%
-
-
-
-
Beta
-0.0244468
-
-
Volatility
3.14%, 8.36%
Prev Close
-0.63%
Price
198.06
Change
-3.35%
0R1B.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 67.95 | 76.79 | 69.77 | 64.92 | 65.08 | |
| Net income per share | 31.47 | 24.86 | 10.44 | 20.97 | 8.02 | |
| Operating cash flow per share | 37.83 | 26.29 | 24.41 | 9.53 | 10.69 | |
| Free cash flow per share | 34.25 | 22.86 | 22.43 | 7.85 | -39.32 | |
| Cash per share | 23.92 | 16.22 | 25.5 | 33.67 | 7.26 | |
| Book value per share | 71.32 | 66.5 | 73.08 | 92.21 | 102.28 | |
| Tangible book value per share | 21.67 | 11.43 | 19.97 | 39.84 | 59.3 | |
| Share holders equity per share | 71.32 | 66.5 | 73.08 | 92.21 | 102.28 | |
| Interest debt per share | 33.59 | 48.48 | 51.32 | 45.71 | 50.43 | |
| Market cap | 63.99B | 55.03B | 36.06B | 39.68B | 37.31B | |
| Enterprise value | 67.52B | 61.61B | 41.49B | 42.97B | 43.69B | |
| P/E ratio | 10.87 | 13.76 | 23.17 | 13.02 | 32.13 | |
| Price to sales ratio | 5.03 | 4.45 | 3.47 | 4.21 | 3.96 | |
| POCF ratio | 9.04 | 13.01 | 9.91 | 28.66 | 24.11 | |
| PFCF ratio | 9.98 | 14.96 | 10.78 | 34.77 | -6.56 | |
| P/B Ratio | 4.8 | 5.14 | 3.31 | 2.96 | 2.52 | |
| PTB ratio | 4.8 | 5.14 | 3.31 | 2.96 | 2.52 | |
| EV to sales | 5.31 | 4.99 | 3.99 | 4.56 | 4.64 | |
| Enterprise value over EBITDA | 10.73 | 14.47 | 12.38 | 15.39 | 20.55 | |
| EV to operating cash flow | 9.54 | 14.57 | 11.4 | 31.04 | 28.24 | |
| EV to free cash flow | 10.54 | 16.75 | 12.4 | 37.66 | -7.68 | |
| Earnings yield | 0.09 | 0.07 | 0.04 | 0.08 | 0.03 | |
| Free cash flow yield | 0.1 | 0.07 | 0.09 | 0.03 | -0.15 | |
| Debt to equity | 0.45 | 0.7 | 0.68 | 0.48 | 0.47 | |
| Debt to assets | 0.22 | 0.31 | 0.31 | 0.26 | 0.26 | |
| Net debt to EBITDA | 0.56 | 1.55 | 1.62 | 1.18 | 3 | |
| Current ratio | 1.72 | 1.84 | 1.83 | 2.99 | 2 | |
| Interest coverage | 22.75 | 13.06 | 9.88 | 8.62 | 6.07 | |
| Income quality | 1.2 | 1.06 | 2.34 | 0.45 | 1.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.18 | 0.19 | 0.25 | 0.25 | 0 | |
| Research and developement to revenue | 0.16 | 0.31 | 0.22 | 0.21 | 0.23 | |
| Intangibles to total assets | 0.34 | 0.36 | 0.33 | 0.31 | 0.23 | |
| Capex to operating cash flow | -0.09 | -0.13 | -0.08 | -0.18 | -4.68 | |
| Capex to revenue | -0.05 | -0.04 | -0.03 | -0.03 | -0.77 | |
| Capex to depreciation | -1.44 | -1.21 | -0.61 | -0.47 | -14.63 | |
| Stock based compensation to revenue | 0.02 | 0.02 | 0.02 | 0.03 | -0.11 | |
| Graham number | 224.72 | 192.88 | 131 | 208.58 | 135.89 | |
| ROIC | 0.25 | 0.16 | 0.15 | 0.09 | 0.07 | |
| Return on tangible assets | 0.33 | 0.25 | 0.1 | 0.18 | 0.06 | |
| Graham Net | -38.29 | -56.2 | -46.73 | -27.52 | -56.37 | |
| Working capital | 3.52B | 3.14B | 3.56B | 6.52B | 3.43B | |
| Tangible asset value | 4.05B | 1.84B | 2.98B | 5.79B | 8.58B | |
| Net current asset value | -5.51B | -7.05B | -5.06B | -1.37B | -5.19B | |
| Invested capital | 0.45 | 0.7 | 0.68 | 0.48 | 0.47 | |
| Average receivables | 2.48B | 2.4B | 2.14B | 2.05B | 2.12B | |
| Average payables | 450.65M | 492.85M | 522.05M | 540.35M | 447.4M | |
| Average inventory | 867.05M | 936.4M | 1.21B | 1.35B | 1.94B | |
| Days sales outstanding | 70.93 | 68.75 | 68.83 | 82.66 | 81.4 | |
| Days payables outstanding | 80.06 | 73.4 | 82.81 | 64.14 | 48.61 | |
| Days of inventory on hand | 121.29 | 172.42 | 189.95 | 175.44 | 304.64 | |
| Receivables turnover | 5.15 | 5.31 | 5.3 | 4.42 | 4.48 | |
| Payables turnover | 4.56 | 4.97 | 4.41 | 5.69 | 7.51 | |
| Inventory turnover | 3.01 | 2.12 | 1.92 | 2.08 | 1.2 | |
| ROE | 0.44 | 0.37 | 0.14 | 0.23 | 0.08 | |
| Capex per share | -3.58 | -3.43 | -1.98 | -1.67 | -50.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 17.3 | 16.14 | 16.25 | 16.82 | 15.87 | |
| Net income per share | 3.82 | 2.69 | 4.09 | -0.47 | 1.72 | |
| Operating cash flow per share | -1.21 | 3.15 | 3.37 | 4.09 | 0.09 | |
| Free cash flow per share | -1.82 | 2.66 | 2.76 | 3.49 | -48.16 | |
| Cash per share | 33.95 | 34.91 | 42.01 | 15.8 | 7.25 | |
| Book value per share | 92.98 | 95.54 | 99.98 | 100.03 | 102.14 | |
| Tangible book value per share | 40.18 | 43.09 | 47.89 | 2.26 | 59.21 | |
| Share holders equity per share | 92.98 | 95.54 | 99.98 | 100.03 | 102.14 | |
| Interest debt per share | 44.64 | 43.94 | 43.77 | 50.76 | 49 | |
| Market cap | 39.35B | 40.17B | 41.16B | 37.36B | 37.36B | |
| Enterprise value | 42.64B | 43.88B | 45.14B | 42.79B | 43.74B | |
| P/E ratio | 17.87 | 25.89 | 17.4 | -137.17 | 37.41 | |
| Price to sales ratio | 15.78 | 17.23 | 17.51 | 15.34 | 16.25 | |
| POCF ratio | -224.87 | 88.22 | 84.53 | 63.07 | 2.99K | |
| PFCF ratio | -149.97 | 104.68 | 102.91 | 74.02 | -5.35 | |
| P/B Ratio | 2.94 | 2.91 | 2.85 | 2.58 | 2.52 | |
| PTB ratio | 2.94 | 2.91 | 2.85 | 2.58 | 2.52 | |
| EV to sales | 17.1 | 18.82 | 19.2 | 17.57 | 19.02 | |
| Enterprise value over EBITDA | 56.65 | 79.06 | 65.36 | 135.76 | 77.37 | |
| EV to operating cash flow | -243.68 | 96.37 | 92.68 | 72.23 | 3.5K | |
| EV to free cash flow | -162.52 | 114.35 | 112.84 | 84.77 | -6.27 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | -0.01 | 0.01 | 0.01 | 0.01 | -0.19 | |
| Debt to equity | 0.48 | 0.46 | 0.43 | 0.5 | 0.47 | |
| Debt to assets | 0.26 | 0.26 | 0.25 | 0.26 | 0.26 | |
| Net debt to EBITDA | 4.37 | 6.69 | 5.75 | 17.22 | 11.28 | |
| Current ratio | 2.99 | 3.24 | 3.27 | 1.68 | 2 | |
| Interest coverage | 9.36 | 7.08 | 11.67 | 2.98 | 5.95 | |
| Income quality | -0.32 | 1.17 | 0.82 | -8.7 | 0.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.24 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.22 | 0.22 | 0.22 | 0.28 | 0.22 | |
| Intangibles to total assets | 0.31 | 0.31 | 0.3 | 0.5 | 0.23 | |
| Capex to operating cash flow | 0.5 | -0.16 | -0.18 | -0.15 | -559.3 | |
| Capex to revenue | -0.04 | -0.03 | -0.04 | -0.04 | -3.04 | |
| Capex to depreciation | -0.36 | -0.64 | -0.74 | -0.7 | -49.9 | |
| Stock based compensation to revenue | 0.03 | 0.03 | 0.03 | 0.18 | -0.11 | |
| Graham number | 89.39 | 75.99 | 95.9 | 32.53 | 62.93 | |
| ROIC | 0.02 | 0.02 | 0.02 | 0 | 0.02 | |
| Return on tangible assets | 0.03 | 0.02 | 0.03 | 0 | 0.01 | |
| Graham Net | -27.75 | -24.99 | -16.3 | -57.16 | -56.29 | |
| Working capital | 6.52B | 6.75B | 7.25B | 3.43B | 3.43B | |
| Tangible asset value | 5.79B | 6.22B | 6.93B | 327.6M | 8.58B | |
| Net current asset value | -1.37B | -1.05B | -264.6M | -5.26B | -5.19B | |
| Invested capital | 0.48 | 0.46 | 0.43 | 0.5 | 0.47 | |
| Average receivables | 2.06B | 2.08B | 2.08B | 2.17B | 2.15B | |
| Average payables | 437.35M | 491.35M | 468.3M | 442.75M | 421.7M | |
| Average inventory | 1.36B | 1.31B | 1.31B | 2.16B | 2.75B | |
| Days sales outstanding | 77.11 | 78.3 | 81.31 | 81.67 | 82.19 | |
| Days payables outstanding | 54.57 | 57.04 | 56.45 | 50.48 | 47.86 | |
| Days of inventory on hand | 149.27 | 148.74 | 169.01 | 342.11 | 299.93 | |
| Receivables turnover | 1.17 | 1.15 | 1.11 | 1.1 | 1.1 | |
| Payables turnover | 1.65 | 1.58 | 1.59 | 1.78 | 1.88 | |
| Inventory turnover | 0.6 | 0.61 | 0.53 | 0.26 | 0.3 | |
| ROE | 0.04 | 0.03 | 0.04 | 0 | 0.02 | |
| Capex per share | -0.61 | -0.5 | -0.6 | -0.6 | -48.25 |
0R1B.L Frequently Asked Questions
What is Biogen Inc stock symbol ?
Biogen Inc is a US stock , located in Cambridge of Massachusetts and trading under the symbol 0R1B.L
What is Biogen Inc stock quote today ?
Biogen Inc stock price is $198.06 today.
Is Biogen Inc stock public?
Yes, Biogen Inc is a publicly traded company.
Company Profile
- Market Capitalization 29.2B
- Employee 7.4K
- CEO Mr. Michel Vounatsos
- Headquarters Cambridge,MASSACHUSETTS,US
- IPO Date 1991-09-17
-
Website
https://www.biogen.com/ 
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
